See more : Rungta Irrigation Limited (RUNGTAIR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PMV Pharmaceuticals, Inc. (PMVP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PMV Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TFI International Inc. (TFII) Income Statement Analysis – Financial Results
- Q Technology (Group) Company Limited (1478.HK) Income Statement Analysis – Financial Results
- TD Power Systems Limited (TDPOWERSYS.BO) Income Statement Analysis – Financial Results
- CVS Group plc (CVSG.L) Income Statement Analysis – Financial Results
- Unisys Corporation (UIS.SW) Income Statement Analysis – Financial Results
PMV Pharmaceuticals, Inc. (PMVP)
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| Gross Profit | -1.26M | -650.00K | -1.28M | -318.00K | -388.00K | -338.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 55.89M | 51.99M | 36.49M | 23.93M | 20.76M | 13.85M |
| General & Administrative | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.25M | 25.05M | 21.80M | 11.01M | 5.88M | 5.04M |
| Other Expenses | 0.00 | 87.00K | 21.00K | -143.00K | -8.00K | 16.00K |
| Operating Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Cost & Expenses | 80.13M | 77.04M | 58.29M | 34.94M | 26.64M | 18.89M |
| Interest Income | 11.17M | 3.63M | 449.00K | 651.00K | 1.30M | 1.34M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.26M | 650.00K | 1.28M | 318.00K | 388.00K | 338.00K |
| EBITDA | -78.88M | -76.73M | -57.99M | -34.62M | -26.25M | -18.55M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.13M | -77.04M | -58.29M | -34.94M | -26.64M | -18.89M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.17M | 3.71M | 470.00K | 508.00K | 1.29M | 1.36M |
| Income Before Tax | -68.96M | -73.33M | -57.82M | -34.43M | -25.34M | -17.54M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | -9.00K | 23.00K | 6.00K | 8.00K | 3.00K |
| Net Income | -68.96M | -73.32M | -57.85M | -34.44M | -25.35M | -17.54M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| EPS Diluted | -1.44 | -1.61 | -1.28 | -0.77 | -0.59 | -0.56 |
| Weighted Avg Shares Out | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
| Weighted Avg Shares Out (Dil) | 48.01M | 45.59M | 45.14M | 44.78M | 43.00M | 31.23M |
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2023, and...
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for PMV Pharmaceuticals, Inc. (PMVP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the...
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the...
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 239.3% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that updated Phase 1 clinical data from its ongoing Phase...
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 182.6% in PMV Pharmaceuticals, Inc. (PMVP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross
After reaching an important support level, PMV Pharmaceuticals, Inc. (PMVP) could be a good stock pick from a technical perspective. PMVP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple...
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2023, and...
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
PRINCETON, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive...
Source: https://incomestatements.info
Category: Stock Reports